TEL AVIV, Israel--(BUSINESS WIRE)--VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced the initiation of a phase 2 study to evaluate the efficacy and safety of its lead compound, VB-201, among patients with elevated high sensitivity C-reactive protein (hsCRP) who are currently taking statins.
